Biology and management of mantle cell lymphoma

Current Opinion in Oncology

Volumn 13, Issue 5, 2001, Pages 342-347

  Leonard, John P ^a   Schattner, Elaine J ^a   Coleman, Morton ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CD19 ANTIGEN; CD20 ANTIGEN; CD22 ANTIGEN; CD23 ANTIGEN; CD5 ANTIGEN; COMMON ACUTE LYMPHOBLASTIC LEUKEMIA ANTIGEN; CYCLIN D1; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; MELPHALAN; METHOTREXATE; MONOCLONAL ANTIBODY; TUMOR MARKER; VINCRISTINE;

CELL PROLIFERATION; CHROMOSOME ANALYSIS; CLINICAL FEATURE; GENE OVEREXPRESSION; IMMUNOHISTOCHEMISTRY; LYMPH NODE METASTASIS; MANTLE CELL LYMPHOMA; NONHODGKIN LYMPHOMA; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEX DIFFERENCE; STEM CELL TRANSPLANTATION;

AGE OF ONSET; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHROMOSOMES, HUMAN, PAIR 11; CHROMOSOMES, HUMAN, PAIR 14; CYCLIN D1; DISEASE PROGRESSION; FEMALE; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; MIDDLE AGED; PROGNOSIS; RISK FACTORS; TRANSLOCATION, GENETIC;

EID: 0034873831     PISSN: 10408746     EISSN: None     Source Type: Journal    
DOI: 10.1097/00001622-200109000-00005     Document Type: Review

References (58)

1. A revised European-American classification of lymphoid neoplasms; a proposal from the International Lymphoid Study Group
2. Histopathology of malignant lymphomas
3. National Cancer Institute sponsored study of classifications of non-Hodgkin's lymphomas; summary and description of a Working Formulation for clinical usage
4. For the Non-Hodgkin's Lymphoma Classification Project: Epidemiology of the non-Hodgkin's lymphomas; distributions of the major subtypes differ by geographic locations
5. Mantle cell lymphoma - An entity comes of age
6. Mantle cell lymphoma
7. BCL-1/cyclin D1 oncoprotein oscillates and subverts the G1 phase control in B-cell neoplasms carrying the t(11;14) translocation
8. Quantitative real-time reverse transcription-PCR assay for cyclin D1 expression: Utility in the diagnosis of mantle cell lymphoma
9. In situ hybridization and reverse transcription-polymerase chain reaction for cyclin D1 mRNA in the diagnosis of mantle cell lymphoma in paraffin-embedded tissues
10. Cyclin D1 by flow cytometry as a useful tool in the diagnosis of B-cell malignancies
11. Immunohistochemical detection of cyclin D1 using optimized conditions is highly specific for mantle cell lymphoma and hairy cell leukemia
12. Rearrangement of CCN D1 (BCL1/PRAD1) 3′ untranslated region in mantle-cell lymphomas and the t(11q13)-associated leukemias
13. Diagnostic utility of fluorescence in situ hybridization in mantle-cell lymphoma
14. Regulation of the retinoblastoma protein-related protein p107 by G1 cyclin-associated kinases
15. Expression of the retinoblastoma protein in low-grade B-cell lymphoma: Relationship to cyclin D1
16. Deletion of cyclin-dependent kinase 4 inhibitor genes p15 and p15 in non-Hodgkin's lymphoma
17. Deletions and loss of expression of P16 INK4 and P21 Wafl genes are associated with aggressive variants of mantle cell lymphomas
18. Alterations of the cyclin D1/p16-pRB pathway in mantle celt lymphoma
19. P53 overexpression as a marker of poor prognosis in mantle cell lymphomas with t(11;14)(q13;q32)
20. The ATM gene in the pathogenesis of mantle-cell lymphoma
21. Mantle cell lymphoma is characterized by inactivation of the ATM gene
22. Cyctin D1/bcl-1 cooperates with myc genes in the generation of B-cell lymphoma in transgenic mice
23. c-myc mRNA expression and genomic alterations in mantle cell lymphomas and other nodal non-Hodgkin's lymphomas
24. Regulation of TCL1 expression in B- and T-cell lymphomas and reactive lymphoid tissues
25. BCMSUN, a candidate gene for B-cell chronic lymphocytic leukemia and mantle-cell lymphoma, has an independently expressed homolog on 1 p22-p31, BCMSUN-like
26. Distribution and pattern of BCL-6 mutations throughout the spectrum of B-cell neoplasia
27. CD40 and its ligand: Central players in B lymphocyte survival, growth, and differentiation
28. Repression of apoptosis in human B-lymphoma cells by CD40-ligand and Bcl-2: Relationship to the cell-cycle and role of the retinoblastoma protein
29. Differential responses to CD40 ligation among Burkitt lymphoma lines that are uniformly responsive to Epstein-Barr virus latent membrane protein 1
30. Soluble CD40 ligand induces selective proliferation of lymphoma cells in primary mantle cell lymphoma cell cultures
31. Proliferative response of mantle cell lymphoma cells stimulated by CD40 ligation and IL-4
32. Mantle cell lymphoma proliferates upon IL-10 in the CD40 system
33. Mantle cell lymphema-molecular and immunophenotypic diagnostic aids
34. Mantle cell lymphoma-presenting features, response to therapy, and prognostic factors
35. Mantle cell lymphoma: A retrospective study of 121 cases
36. Mantle cell lymphoma, A clinicopathologic study of 68 cases from the Nebraska Lymphoma Study Group
37. Increased proteasome degradation of cyclin-dependent kinase inhibitor p27 is associated with a decreased overall survival in mantle cell lymphoma
38. Significance of cyclin D1 overexpression for the diagnosis of mantle cell lymphoma: A clinicopathologic comparison of cyclin D1-positive MOL and cyclin D1-negative MCL-like B-cell lymphoma
39. Multicentre randomized therapeutic trial for advanced centrocytic lymphoma: Anthracycline does not improve the prognosis
40. Patterns of survival in mantle cell lymphoma
41. Purine analog (PA) therapy for untreated mantle cell (MCL) and monocytoid (MNL) lymphomas; immunophenotype does not predict response to fludarabine (FLUD) and cladribine (2CdA)
42. Management of mantle cell lymphoma
43. Multicenter phase II study of fludarabine phosphate for patients with newly diagnosed lymphoplasmacytoid lymphoma, Waldenstrom's macroglobulinemia, and mantle-cell lymphoma
44. Randomized trial of fludarabine versus fludarabine and idarubicin as frontline treatment in patients with indolent or mantle-cell lymphoma
45. The PEP-C (C3) oral combination chemotherapy regimen for refractory/relapsed lymphoma: Daily prednisone, etoposide, procarbazine and cyclophosphamide
46. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma
47. Treatment of mantle-cell lymphoma with rituximab (chimeric monoclonal anti-CD20 antibody): Analysis of factors associated with response
48. Rituxan/CHOP induction therapy in newly diagnosed patients with mantle cell lymphoma
49. Hyper-CVAD and high-dose methotrexate/cytarabine followed by stem-cell transplantation: An active regimen for aggressive mantle-cell lymphoma
50. Dexa-BEAM: An effective regimen for cytoreduction prior to high-dose chemotherapy with autologous stem cell support for patients with relapsed/refractory mantle-cell lymphoma
51. High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: No evidence for long-term remission
52. Autologous hematopoietic stem cell transplantation for mantle cell lymphoma
53. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease
54. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: Evidence for a role of both chemotherapy and rituximab infusion
55. Allogeneic hematepoietic transplantation for mantle-cell lymphoma: Molecular remissions and evidence of graft-versus-malignancy
56. Allogeneic bone marrow transplantation for refractory mantle cell lymphoma
57. Patients with mantle-cell lymphoma relapsing after autologous stem celt transplantation may be rescued by allogeneic transplantation
58. Successful allogeneic stem-cell transplantation with prophylactic stepwise G-CSF primed-DLIs for relapse after autologous transplantation in mantle cell lymphoma: A case report and literature on the evidence of GVL effects in MCL